Inhibition of branched-chain alpha-keto acid dehydrogenase kinase augments the sensitivity of ovarian and breast cancer cells to paclitaxel

Ibrahim, Suad Lateef; Abed, Mohammed Najim; Mohamed, Gehad; Price, Joshua C.; Abdullah, Marwan Ibrahim; Richardson, Alan

Abstract

Many cancer patients who initially respond to chemotherapy eventually develop chemoresistance, and to address this,
we previously conducted a RNAi screen to identify genes contributing to resistance. One of the hits from the screen was branchedchain α-keto acid dehydrogenase kinase (BCKDK). BCKDK controls the metabolism of branched-chain amino acids (BCAAs) through
phosphorylation and inactivation of the branched-chain α-keto acid dehydrogenase complex (BCKDH), thereby inhibiting
catabolism of BCAAs

Citation

Ibrahim, S. L., Abed, M. N., Mohamed, G., Price, J. C., Abdullah, M. I., & Richardson, A. (2023). Inhibition of branched-chain alpha-keto acid dehydrogenase kinase augments the sensitivity of ovarian and breast cancer cells to paclitaxel. British Journal of Cancer, 128(5), 896-906. https://doi.org/10.1038/s41416-022-02095-9

• Journal Article Type: Article
• Acceptance Date: Dec 16, 2022
• Online Publication Date: Dec 16, 2022
• Publication Date: Mar 23, 2023
• Deposit Date: Jun 1, 2023
• Journal: British Journal of Cancer
• Print ISSN: 0007-0920
• Electronic ISSN: 1532-1827
• Publisher: Cancer Research UK
• Peer Reviewed: Peer Reviewed
• Volume: 128
• Issue: 5
• Pages: 896-906
• DOI: https://doi.org/10.1038/s41416-022-02095-9
• Keywords: Cancer Research; Oncology
• Public URL: https://keele-repository.worktribe.com/output/434077
• Publisher URL: https://www.nature.com/articles/s41416-022-02095-9
• Additional Information: Received: 25 August 2022; Revised: 24 November 2022; Accepted: 28 November 2022; First Online: 16 December 2022; : The authors declare no competing interests.; : Not applicable.